Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will engage in a fireside chat on Tuesday, February 11, 2025, at 12:40 p.m. ET.
The company, which focuses on developing innovative treatments for cancer and inflammatory diseases, will make the event available through a live webcast. Interested parties can access the webcast through the Investors section of Nurix's website, and the recording will remain accessible for 30 days following the event.
Nurix Therapeutics (NRIX), una compagnia biofarmaceutica in fase clinica specializzata in medicinali per la degradazione mirata delle proteine, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Salute di Oppenheimer. Il presidente e CEO dell'azienda, Arthur T. Sands, M.D., Ph.D., parteciperà a una chiacchierata informale martedì 11 febbraio 2025, alle 12:40 EST.
L'azienda, che si concentra sullo sviluppo di trattamenti innovativi per il cancro e le malattie infiammatorie, renderà l'evento disponibile tramite una diretta web. Le parti interessate potranno accedere alla diretta attraverso la sezione Investitori del sito web di Nurix, e la registrazione rimarrà accessibile per 30 giorni dopo l'evento.
Nurix Therapeutics (NRIX), una empresa biofarmacéutica en etapa clínica especializada en medicamentos de degradación proteica dirigida, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. El presidente y CEO de la compañía, Arthur T. Sands, M.D., Ph.D., participará en una charla informal el martes 11 de febrero de 2025, a las 12:40 p.m. ET.
La empresa, que se centra en el desarrollo de tratamientos innovadores para el cáncer y enfermedades inflamatorias, hará que el evento esté disponible a través de una transmisión en vivo. Las partes interesadas podrán acceder a la transmisión a través de la sección de Inversores en el sitio web de Nurix, y la grabación permanecerá accesible durante 30 días después del evento.
Nurix Therapeutics (NRIX), 임상 단계의 생명 공학 회사로 표적 단백질 분해 약물을 전문으로 하고 있습니다. 회사는 오펜하이머 제35회 연례 건강 및 생명 과학 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 회장 겸 CEO인 Arthur T. Sands, M.D., Ph.D.는 2025년 2월 11일 화요일 오후 12:40(동부 표준시)에 대화에 참여할 것입니다.
회사는 암 및 염증 질환에 대한 혁신적인 치료법 개발에 집중하고 있으며, 이번 행사를 생중계로 제공할 예정입니다. 관심 있는 분들은 Nurix 웹사이트의 투자자 섹션을 통해 웹캐스트에 접속할 수 있으며, 행사가 끝난 후 30일 동안 녹화된 내용을 확인할 수 있습니다.
Nurix Therapeutics (NRIX), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments de dégradation ciblée des protéines, a annoncé sa participation à la 35ème Conférence Annuelle sur les Sciences de la Vie et la Santé d'Oppenheimer. Le président et PDG de l'entreprise, Arthur T. Sands, M.D., Ph.D., participera à une discussion informelle le mardi 11 février 2025, à 12h40 ET.
L'entreprise, qui se concentre sur le développement de traitements innovants pour le cancer et les maladies inflammatoires, rendra l'événement disponible via un webinaire en direct. Les parties intéressées pourront accéder au webinaire via la section Investisseurs du site Web de Nurix, et l'enregistrement restera accessible pendant 30 jours après l'événement.
Nurix Therapeutics (NRIX), ein klinisches biopharmazeutisches Unternehmen, das sich auf gezielte Proteinabbau-Medikamente spezialisiert hat, hat seine Teilnahme an der 35. Jährlichen Healthcare Life Sciences Konferenz von Oppenheimer angekündigt. Der Präsident und CEO des Unternehmens, Arthur T. Sands, M.D., Ph.D., wird am Dienstag, dem 11. Februar 2025, um 12:40 Uhr ET an einem Gespräch teilnehmen.
Das Unternehmen, das sich auf die Entwicklung innovativer Behandlungen für Krebs und entzündliche Erkrankungen konzentriert, wird das Event über einen Live-Stream verfügbar machen. Interessierte Parteien können über den Investorenbereich der Nurix-Website auf den Live-Stream zugreifen, und die Aufzeichnung wird 30 Tage lang nach der Veranstaltung zugänglich bleiben.
- None.
- None.
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 12:40 p.m. ET.
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the Oppenheimer Healthcare Conference 2025?
How long will the NRIX Oppenheimer Conference webcast be available?
What therapeutic areas does Nurix Therapeutics (NRIX) focus on?
Where can investors access the NRIX Oppenheimer Conference webcast?
What type of presentation will NRIX deliver at the Oppenheimer Conference?
